ZAMÓW NEWSLETTER
Aktualności
 
Dodane 25.07.2011
Small intestine-derived gastrointestinal stromal tumour diagnosed synchronously with colon adenocarcinoma: a case report and review of the literature
Gastrointestinal stromal tumours (GISTs) account for 0.1-3% of all gastrointestinal cancers. Although nausea, emesis, abdominal pain, GIS haemorrhage, and non-specific symptoms associated with metastatic disease are common, asymptomatic cases are not rare. They are located in the stomach in approximately 60-70% of cases, and in the small intestine in 20-30% of cases. Gastrointestinal stromal tumours can be seen synchronously or metachronously with other epithelial cancers. The co-occurrence of colon adenocarcinomas and GISTs in the small intestine is not common. The genetic pathways in the tumourigenesis of two different neoplasms (GIST and colorectal adenocarcinoma) being different was suggested as a probable cause; however; although the number of cases is limited, some researchers have reported that they could not rule out the possibility that this association is not coincidental. Herein we present a patient who was concomitantly diagnosed with a GIST as a result of an ileal lesion biopsy performed during surgery for colon adenocarcinoma.
 
Dodane 25.07.2011
PET/CT in recognition of a complicated case of adenocarcinoma within ileal pouch-anal anastomosis in a patient after restorative proctocolectomy for familial adenomatous polyposis
 
Dodane 25.07.2011
Radiation recall dermatitis induced by Amol during tamoxifen therapy – case report
In the course of radiation therapy different types of adverse reactions of the skin are observed in approximately 95% of patients. Among the various complications encountered after radiotherapy, radiation recall dermatitis (RRD) deserves special attention. Radiation dermatitis is a form of delayed hypersensitivity of irradiated skin, and the direct trigger factors are medicines – most chemotherapeutics. The reaction is an inflammatory dermatosis. It is limited to previously irradiated skin and appears a number of months after radiotherapy. The aetiology of RRD is still unclear. Its clinical presentation may vary from mild erythema to necrosis and ulceration. The article presents the case of a 50-year-old patient, who after radiotherapy for breast cancer, during the hormonal therapy (tamoxifen), developed RRD type skin reactions after skin application of Amol. The article presents a detailed differential diagnosis of skin changes of RRD type, and discusses the principles of treatment and prevention.
 
Dodane 25.07.2011
Palmar-plantar erythrodysaesthesia during pegylated liposomal doxorubicin treatment – case report
Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome (HFS), is a distinctive and relatively frequent dermatological toxic reaction associated with certain chemotherapeutic agents: pegylated liposomal doxorubicin, capecitabine, a long-circulating formulation of doxorubicin, cytosine arabinoside, interleukin 2. HFS typically presents with dysaesthesia and tingling in the hands and feet. Dysaesthesias and erythema may occur on several other body surfaces, especially in areas where pressure or increased warmth occurs, such as on the buttocks, groin, under pendulous breasts, and in the axillae. We present the case of a 56-year-old woman with HFS in the axillae, inguen and on the skin of the back and abdomen during treatment with pegylated liposomal doxorubicin for metastatic breast cancer. After four cycles of chemotherapy, treatment was interrupted due to HFS (G3 according to NCI CTC). Palmar-plantar erythrodysaesthesia is an oppressive complication after chemotherapy; it often makes normal daily activity impossible, deteriorates the patient’s quality of life and frequently limits chances of effective treatment.
 
Dodane 25.07.2011
Cerebral complications induced by calcineurin inhibitors in children after haematopoietic stem cell transplantation
Calcineurin inhibitors (CI), such as tacrolimus and cyclosporin A (CSA), are routinely used for prophylaxis and therapy of graft-versus-host disease (GVHD) after haematopoietic stem cell transplantation (HSCT) and solid organ transplantation. Neurotoxicity is a well-known side effect of calcineurin inhibitor therapy with multifactorial pathogenesis. In this paper we report the clinical and radiological features of CI-induced cerebral complications in four paediatric patients after haematopoietic stem cell transplantation. The most common symptoms in this series of patients were seizures and disturbances of consciousness. Abnormalities in neuroimaging suggested CI-induced leukoencephalopathy or reversible posterior leukoencephalopathy syndrome or showed cerebral haemorrhage. Other possible causes of neurological complications, such as delayed cyclosporin A toxicity, post-transplant microangiopathy, hypertension or thrombocytopenia are discussed. We also present a review of the literature of tacrolimus-induced neurotoxicity in children. So far, 47 case reports of children and adolescents up to 21 years of age with tacrolimus-induced encephalopathy have been described in the literature. The clinical features of tacrolimus-induced leukoencephalopathy in children are similar to those reported in adults.
 
Dodane 25.07.2011
Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation
Post-transplant lymphoproliferative disease (PTLD) after haematopoietic stem cell transplantation is a life-threatening complication and the number of patients at risk is increasing over time. In the majority of patients Epstein-Barr virus-related PTLD (EBV-PTLD) is diagnosed with a histological picture of B-cell lymphoma. In 2009 recommendations for diagnosis, monitoring and treatment of patients with EBV-PTLD were published. Definitions of preemptive treatment and therapy of probable or proven PTLD were introduced. Results of preemptive treatment and therapy of documented PTLD are discussed in this paper, with the emphasis on monoclonal antibody anti-CD20 rituximab effectiveness and indications for its applications. A comprehensive review of reported cases of PTLD and summary of results indicate that rituximab in monotherapy or in combination treatment is successful in 63% of confirmed PTLD cases and in 89% when used preemptively. Still, an analysis of factors determining the response to therapy is lacking.
 
Dodane 25.07.2011
Bone tissue as the site of action of oncological drugs
Anticancer therapy has multiple, sometimes life-threatening side effects, and their influence on bone is not seen as important. Data have been published confirming the existence of side effects chemotherapy has on bone, which affect patients’ quality of life. They influence a bone tissue not only in a direct way, but also when suppressing the activity of gonads. We have no information on the impact of drugs on bone belonging to the “targeted therapies”. There are, however, some attempts to create antibodies that target proteins involved in bone physiology. Relatively well known is the impact of anti-cancer hormone therapy on bone metabolism. The most commonly used drugs in this type of therapy are: analogues of luteinizing hormone-releasing hormone (LHRH), selective oestrogen receptor modulators (SERMs), aromatase inhibitors and antiandrogens. A group of preparations particularly connected with this issue is the bisphosphonates, entering into interaction both with bone cells and colonizing tumour cells.
 
Dodane 25.07.2011
The stability of fludarabine phosphate in concentrate and diluted with sodium chloride 0.9%
 
Dodane 25.07.2011
Elevated levels of serum transforming growth factor-β 1 in oesophageal squamous cell carcinoma patients
Transforming growth factor- β 1 (TGF- β 1) is a multifunctional cytokine involved in cancer development. The diagnostic significance of serum levels of transforming growth factor- β 1 (sTGF- β 1) in the oesophageal squamous cell carcinoma (ESCC) remains unclear. The aim of the study was to analyze sTGF- β 1 concentrations in ESCC patients. The sTGF- β 1 levels were assessed according to the clinical parameters in cancer patients. We determined sTGF- β 1 concentrations in ESCC patients before and after oesophagectomy. The correlation between sTGF- β 1 and serum levels of vascular endothelial growth factor (sVEGF-A) was examined as well. Serum TGF- β 1 level was significantly higher in ESCC compared to the control group (p < 0.001). Serum levels of TGF- β 1 positively correlated with the depth of tumour invasion (p = 0.042). There were no differences in sTGF- β 1 levels in patients stratified by the presence of regional and distant metastases and stage of cancer progression. The level of sTGF- β 1 was significantly lower in ESCC patients after oesophagectomy than before surgical treatment (p = 0.002). A positive correlation between sTGF- β 1 and sVEGF-A (p = 0.017) was observed.
 
Dodane 25.07.2011
Frequency of deletion of CDKN2A (9p21) gene in T-cell lymphomas in FISH analysis
Cytogenetic investigations play an important role in the diagnosis of lymphomas. One of the recurrent aberrations in T-cell non-Hodgkin lymphoma (T-NHL) is a loss of the suppressor gene CDKN2A (9p21). The loss of this region is not seen in the karyotype; this deletion is submicroscopic in most cases. Deletion of 9p21 was found in 29% (n = 55) of patients with T-NHL. Loss of CDKN2A was observed in 11 (55%) out of 20 cases with T-LBL/ALL, in 2 (33%) out of 6 with T-LGL and in 3 (20%) out of 15 patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Patients with MF, SS, primary cutaneous peripheral T-cell lymphomas and other sporadic subtypes of peripheral T-cell lymphomas did not show deletion of this region. In studied lymphomas with deletion we observed a heterogeneous signal pattern in most cases (over 81%). Analysis of the signal pattern of CDKN2A deletion showed clones with mono- and biallelic deletion in cells with variable ploidy. Probably, this phenomenon is related to concurrent incidence of cells which are in different stages of neoplastic transformation.
 
Strona:    Poprzednia   5543   5544   5545   5546   5547   5548   5549   5550   5551   ...   Następna
Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Mednauka Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2025 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.